These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 19875393)

  • 21. [Multifactorial relations between HIV, HAART and bone metabolism].
    Borderi M
    Infez Med; 2006 Sep; 14(3):117-24. PubMed ID: 17127825
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reduced bone mineral density in human immunodeficiency virus-infected patients and its association with increased central adiposity and postload hyperglycemia.
    Brown TT; Ruppe MD; Kassner R; Kumar P; Kehoe T; Dobs AS; Timpone J
    J Clin Endocrinol Metab; 2004 Mar; 89(3):1200-6. PubMed ID: 15001610
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review.
    Brown TT; Qaqish RB
    AIDS; 2006 Nov; 20(17):2165-74. PubMed ID: 17086056
    [TBL] [Abstract][Full Text] [Related]  

  • 24. HIV infection and osteoporosis: pathophysiology, diagnosis, and treatment options.
    Rothman MS; Bessesen MT
    Curr Osteoporos Rep; 2012 Dec; 10(4):270-7. PubMed ID: 23100110
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is there enough evidence to use bisphosphonates in HIV-infected patients? A systematic review and meta-analysis.
    Pinzone MR; Moreno S; Cacopardo B; Nunnari G
    AIDS Rev; 2014; 16(4):213-22. PubMed ID: 25300622
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bone disease and HIV infection.
    Rojo P; Ramos JT
    Clin Infect Dis; 2006 Jul; 43(1):111-2; author reply 113-4. PubMed ID: 16758430
    [No Abstract]   [Full Text] [Related]  

  • 27. Influence of HIV Infection and Antiretroviral Therapy on Bone Homeostasis.
    Delpino MV; Quarleri J
    Front Endocrinol (Lausanne); 2020; 11():502. PubMed ID: 32982960
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Decreased bone mineral density and increased fracture risk in aging men with or at risk for HIV infection.
    Arnsten JH; Freeman R; Howard AA; Floris-Moore M; Lo Y; Klein RS
    AIDS; 2007 Mar; 21(5):617-23. PubMed ID: 17314524
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increase in bone mass after correction of vitamin D insufficiency in bisphosphonate-treated patients.
    Geller JL; Hu B; Reed S; Mirocha J; Adams JS
    Endocr Pract; 2008 Apr; 14(3):293-7. PubMed ID: 18463035
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bisphosphonates for osteoporosis in nonmetastatic prostate cancer patients receiving androgen-deprivation therapy: a systematic review and meta-analysis.
    Ding H; Yang L; Du W; Teng Y; Fu SJ; Tao Y; Lu JZ; Wang ZP
    Asian Pac J Cancer Prev; 2013; 14(5):3337-43. PubMed ID: 23803126
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of osteopenia and osteoporosis in anorexia nervosa: a systematic review of the literature.
    Mehler PS; MacKenzie TD
    Int J Eat Disord; 2009 Apr; 42(3):195-201. PubMed ID: 18951456
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Bone mineral loss in patients with human immunodeficiency virus infection].
    Olmos JM; González-Macías J
    Enferm Infecc Microbiol Clin; 2008 Apr; 26(4):212-9. PubMed ID: 18381041
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Osteoporosis and HIV Infection.
    Biver E
    Calcif Tissue Int; 2022 May; 110(5):624-640. PubMed ID: 35098324
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emerging bone problems in patients infected with human immunodeficiency virus.
    Mondy K; Tebas P
    Clin Infect Dis; 2003 Apr; 36(Suppl 2):S101-5. PubMed ID: 12652379
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pathogenesis of osteopenia/osteoporosis induced by highly active anti-retroviral therapy for AIDS.
    Pan G; Yang Z; Ballinger SW; McDonald JM
    Ann N Y Acad Sci; 2006 Apr; 1068():297-308. PubMed ID: 16831930
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Breast cancer outcome in relation to bone mineral density and bisphosphonate use: a sub-study of the DATA trial.
    van Hellemond IEG; Smorenburg CH; Peer PGM; Swinkels ACP; Seynaeve CM; van der Sangen MJC; Kroep JR; de Graaf H; Honkoop AH; Erdkamp FLG; van den Berkmortel FWPJ; de Roos WK; Linn SC; Imholz ALT; de Boer M; Tjan-Heijnen VCG;
    Breast Cancer Res Treat; 2020 Apr; 180(3):675-685. PubMed ID: 32124136
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost effectiveness of fracture prevention in postmenopausal women who receive aromatase inhibitors for early breast cancer.
    Ito K; Blinder VS; Elkin EB
    J Clin Oncol; 2012 May; 30(13):1468-75. PubMed ID: 22370313
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Zoledronic acid for cancer therapy--induced and postmenopausal bone loss.
    Brufsky AM
    Expert Opin Pharmacother; 2008 Apr; 9(6):1013-28. PubMed ID: 18377343
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Alendronate, vitamin D, and calcium for the treatment of osteopenia/osteoporosis associated with HIV infection.
    Mondy K; Powderly WG; Claxton SA; Yarasheski KH; Royal M; Stoneman JS; Hoffmann ME; Tebas P
    J Acquir Immune Defic Syndr; 2005 Apr; 38(4):426-31. PubMed ID: 15764959
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Osteopenia in HIV-infected patients: is it the disease or is it the treatment?
    Knobel H; Guelar A; Vallecillo G; Nogués X; Díez A
    AIDS; 2001 Apr; 15(6):807-8. PubMed ID: 11371701
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.